These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm. Falcone U, Sibai H, Deotare U. Crit Rev Oncol Hematol; 2016 Nov 04; 107():156-162. PubMed ID: 27823644 [Abstract] [Full Text] [Related]
8. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Economides MP, Rizzieri D, Pemmaraju N. Curr Hematol Malig Rep; 2019 Dec 04; 14(6):515-522. PubMed ID: 31853773 [Abstract] [Full Text] [Related]
9. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Cai T, Gouble A, Black KL, Skwarska A, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Zhang Q, Galetto R, Filipe S, Cavazos A, Han L, Kuruvilla V, Ma H, Weng C, Liu CG, Liu X, Konoplev S, Gu J, Tang G, Su X, Al-Atrash G, Ciurea S, Neelapu SS, Lane AA, Kantarjian H, Guzman ML, Pemmaraju N, Smith J, Thomas-Tikhonenko A, Konopleva M. Nat Commun; 2022 Apr 28; 13(1):2228. PubMed ID: 35484100 [Abstract] [Full Text] [Related]
11. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm. Xue T, Budde LE. Hematol Oncol Clin North Am; 2020 Jun 28; 34(3):575-587. PubMed ID: 32336421 [Abstract] [Full Text] [Related]
12. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123. Zanotta S, Galati D, De Filippi R, Pinto A. Int J Mol Sci; 2024 Jan 25; 25(3):. PubMed ID: 38338733 [Abstract] [Full Text] [Related]